Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive

European Journal of Dermatology

Volumn 25, Issue 5, 2015, Pages 452-456

  Gabeff, Romain ^a   Dutartre, Hervé ^a   Khammari, Amir ^a   Boisrobert, Aurélie ^a   Nguyen, Jean Michel ^a   Quereux, Gaëlle ^a   Brocard, Anabelle ^a   Saint Jean, Mélanie ^a   Peuvrel, Lucie ^a   Dreno, Brigitte ^a  

^a CLINIQUE DERMATOLOGIQUE   (France)

Author keywords

B RAF inhibitors; Dabrafenib; Melanoma; Phototoxicity; Vemurafenib; Visible light

Indexed keywords

DABRAFENIB; VEMURAFENIB; B RAF KINASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; MELANOMA; OBSERVATIONAL STUDY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PROSPECTIVE STUDY; RADIATION DERMATITIS; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ADVERSE EFFECTS; AGED; COHORT ANALYSIS; COMPARATIVE STUDY; DERMATITIS, PHOTOTOXIC; DRUG EFFECTS; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR INVASION; ULTRAVIOLET RADIATION;

ADULT; AGED; COHORT STUDIES; DERMATITIS, PHOTOTOXIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; OXIMES; PALLIATIVE CARE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 84953888673     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2015.2628     Document Type: Article

References (18)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Hauschild A, Grob J-J, Demidov LV, et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
3. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: e11-8.
4. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809- 19.
5. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
6. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31: 3205-11.
7. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480- 1.
8. Gelot P, Dutartre H, Khammari A, et al. Vemurafenib: an unusual UVA-induced photosensitivity. Exp Dermatol 2013; 22: 297-8.
9. Brugière C, Stefan A, Morice C, Cornet E, Moreau A, Allouche S, et al. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. Br J Dermatol 2014; 171: 1529-32.
10. Du-Thanh A, Debu A, Lalheve P, Guillot B, Dereure O, Peyron J-L. Solar urticaria: a time-extended retrospective series of 61 patients and review of literature. Eur J Dermatol 2013; 23: 202-7.
11. Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691-7.
12. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-7.
13. Moseley H, Naasan H, Dawe RS, Woods J, Ferguson J. Population reference intervals for minimal erythemal doses in monochromator phototesting. Photodermatol Photoimmunol Photomed 2009; 25: 8-11.
14. Béani JC. [Interpretation of photobiologic tests]. Ann Dermatol Venereol 1987; 114: 123-6.
15. Committee for Medicinal Products for Human Use (CHMP). Assessment Report of Zelboraf, vemurafenib. EMA/CHMP/926998/2011. 2011.
16. FDA/Center for Drug Evaluation and Research, Division of Drug Oncology Products (HFD-150) 2011. Pharmacology and Toxicology NDA Review and Evaluation of Zelboraf, vemurafenib. 2011.
17. Boudon SM, Plappert-Helbig U, Odermatt A, Bauer D. Characterization of vemurafenib phototoxicity in a mouse model. Toxicol Sci Off J Soc Toxicol 2014; 137: 259-67.
18. Shah N, Iyer RM, Mair H-J, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci 2013; 102: 967-81.